The company announced the publication of interim data from the Phase I/II study of a vaccine it is developing with the University of Oxford. The news comes the week after Moderna announced the publication of data for its vaccine.
A joint report by cybersecurity agencies in the U.K. and Canada, endorsed by their U.S. counterparts, states that the hacker group Cozy Bear had been targeting organizations involved with Covid-19 vaccine development efforts.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
The Oncologic Drugs Advisory Committee voted 12-0 that the benefit-risk profile of belantamab mafodotin supported the drug. The vote came despite concerns expressed by the FDA in briefing documents ahead of the ODAC meeting, particularly with regard to ocular toxicity.
The FDA's Oncologic Drugs Advisory Committee will convene Tuesday to discuss the drug, belantamab mafodotin. Despite the drug's first-in-class potential, the briefing document for the meeting raised concerns about eye toxicity and questions about its risk-benefit profile.
The company said Tuesday that a final analysis of its Phase IIb/III study of cabotegravir showed greater efficacy in HIV prevention than Gilead's Truvada. The study, among men and transgender women who have sex with men, was stopped in May following an interim analysis.
AstraZeneca's Phase III AURA3 trial of the lung cancer drug Tagrisso was chosen for the program, Project Patient Voice. However, an FDA spokesperson said no new trials would be added in the coming weeks or months.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
The drug, belantamab mafodotin, could become the first approved therapy for multiple myeloma that targets the cell-surface antigen BCMA. The FDA accepted the application for the drug in January.
Data from a large Phase II/III study in the U.K. showed that patients requiring respiratory support who received the drug dexamethasone died at lower rates than those who received standard treatments alone.
The California-based company is developing drugs that work through "synthetic lethality," whereby they target two genes at once rather than only targeting one.
The arrangement is analogous to the emergency use authorization that the drug received from the FDA earlier this month. Peer-reviewed data from the Phase III NIAID study of the drug were published Friday.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The company said the DREAMM-2 study of belantamab mafodotin, its antibody-drug conjugate that targets BCMA, showed a median overall survival of nealry 15 months in heavily pretreated patients.
The drugmaker licensed the vaccine last month from the University of Oxford, which is developing it in a Phase I/II clinical trial in southern England. The company also plans a Phase III study.
A Phase IIb/III study sponsored by NIAID is being stopped early after an interim analysis indicated that injected cabotegravir provided better protection than Gilead's Truvada.
The drugmaker is partnering with Oxford to develop the adenovirus vector-based vaccine, ChAdOx1 nCoV-19, which entered a Phase I/II clinical trial of more than 1,100 healthy volunteers in the U.K. late last month. Data could be available next month, the company said.
The company said it had initiated a trial of Calquence for treating cytokine storm associated with the disease. The drug is a BTK inhibitor approved for certain forms of leukemia and lymphoma, and the drugmaker said inhibiting BTK may have an effect on overactive immune responses.